ScreenerHero

VBIO Valion Bio, Inc.

NAS · US · Healthcare · Biotechnology · valionbio.com
0.5293USD+4.07%Mkt Cap: 1.14M USDP/E: —

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also c…

Industry Peers

Biotechnology
Screen all Biotechnology
VRTX
Vertex Pharmaceuticals Incorporated
$136.56BUSDP/E 34.7
REGN
Regeneron Pharmaceuticals, Inc.
$98.84BUSDP/E 21.1
MRNA
Moderna, Inc.
$90.38BUSD
CSL
CSL Limited
$66.07BUSD
UCB
UCB SA
$62.48BUSDP/E 26.2
ARGX
argenx SE
$61.05BUSDP/E 35.3
ARGX
argenx SE
$60.37BUSDP/E 33.3
ONC
BeOne Medicines AG
$47.58BUSDP/E 53.4
RPRX
Royalty Pharma plc
$39.85BUSDP/E 45.3
RVMD
Revolution Medicines, Inc.
$37.27BUSD
GMAB
Genmab A/S
$31.67BUSDP/E 43.9
GMAB
Genmab A/S
$31.43BUSDP/E 45.8
ROIV
Roivant Sciences Ltd.
$28.64BUSD
INSM
Insmed Incorporated
$26.58BUSD
INCY
Incyte Corporation
$24.66BUSDP/E 61.7
ALNY
Alnylam Pharmaceuticals, Inc.
$22.11BUSDP/E 8.3
BNTX
BioNTech SE
$21.22BUSD
ASND
Ascendis Pharma A/S
$18.12BUSDP/E 18.1
EXEL
Exelixis, Inc.
$16.84BUSDP/E 20.7
JAZZ
Jazz Pharmaceuticals plc
$15.50BUSDP/E 71.5

Key Statistics

Company
Market Cap1.14M USD
Enterprise Value15.75M USD
Revenue (TTM)-86.00K USD
Gross Profit-54.00K USD
Net Income (TTM)-8.88M USD
Revenue/Share-0.04 USD
Last Price0.5293 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees52
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.95
EV/Revenue-183.17
P/S-13.27
P/B0.02
EPS (TTM)-177.91 USD
EPS (Forward)—
52W Range
0.40003% of range4.390
52W High4.390 USD
52W Low0.4000 USD
Profitability
Gross Margin0.00%
Oper. Margin19652.33%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-52.85%
ROA-28.09%
ROIC-58.83%
ROCE-25.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.00M USD
CapEx (TTM)581.00K USD
FCF Margin9374.71%
FCF Yield-706.61%
Net Debt15.30M USD
Net Debt/EBITDA-0.93
Net Debt/FCF—
Balance Sheet
Debt/Equity0.38
Current Ratio1.11
Quick Ratio0.69
Book Value/Sh25.57 USD
Cash/Share2.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 31, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.16M
Float879.97K
Insiders0.26%
Institutions5.48%
Short Interest
Short Ratio0.1d
Short % Float10.73%
Short % Out.10.71%
Shares Short230.77K
Short (prev mo.)87.97K
Technical
SMA 501.702 (-68.9%)
SMA 20013.71 (-96.1%)
Beta1.91
S&P 52W Chg12.75%
Avg Vol (30d)1.17M
Avg Vol (10d)98.47K
Technical Indicators
RSI (14)30.2
MACD-0.2518
MACD Signal-0.2639
MACD Hist.+0.0122
BB Upper1.190 USD
BB Middle0.7018 USD
BB Lower0.2135 USD
BB Width139.15%
ATR (14)0.1375 USD
Vol Ratio (20d)0.10x

About Valion Bio (NASDAQ: VBIO)

›

Valion Bio (NASDAQ: VBIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 52 employees.

The shares were at 0.5293 USD on 13 November 2026, down 81.8% over 52 weeks. Its 52-week range is 0.4000 USD to 4.390 USD: the price is 87.9% below the high and 32.3% above the low.

Its market capitalisation is 1.14M USD.

Valion Bio reports return on equity of -52.9%.

Its debt exceeds its cash by 15.30M USD, a debt-to-equity ratio of 0.38. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.

Compare VBIO with VRTX and REGN →